CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition

Area of Science:

• Endocrinology and Metabolism
• Molecular Biology
• Drug Discovery

Background:

• Pharmacologic expansion of pancreatic beta cells is a key therapeutic strategy for diabetes.
• Understanding the molecular pathways controlling beta cell growth is crucial for developing new treatments.

Purpose of the Study:

• To identify bioactive compounds that modulate beta cell replication.
• To elucidate the molecular mechanisms underlying beta cell growth induction by identified compounds, particularly CC-401.

Main Methods:

• Screening of approximately 2400 bioactive compounds for their effect on rat beta cell replication.
• In vitro and in vivo studies using rodent and human beta cells.
• Pharmacologic inhibition of specific kinases including dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 1A/B, glycogen synthase kinase-3β (GSK-3β), and activin A receptor type II-like kinase/transforming growth factor-β (ALK5/TGF-β).
• Analysis of downstream signaling pathways including nuclear factor of activated T cells (NFAT), p27Kip1, and the RB-like, E2F and multivulval class B (DREAM) complex.

Main Results:

• CC-401, a c-Jun N-terminal kinase inhibitor, was identified as a potent inducer of rodent and human beta cell replication via DYRK1A/B inhibition.
• Human beta cell replication was enhanced by co-inhibition of GSK-3β or ALK5/TGF-β.
• Contrary to previous hypotheses, NFAT inhibition had minimal impact on CC-401-induced replication.
• CC-401 was shown to inhibit DYRK1A-dependent phosphorylation and stabilization of p27Kip1 and increase expression of replication-promoting genes regulated by the DREAM complex (e.g., MYBL2, FOXM1).

Conclusions:

• The study provides a valuable compendium of compounds for manipulating beta cell replication signaling pathways.
• DYRK1A/B inhibition, particularly by CC-401, represents a promising strategy for beta cell expansion.
• The findings reveal novel mechanisms beyond NFAT activation, involving p27Kip1 stabilization and DREAM complex regulation, in CC-401-mediated beta cell growth.